- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04842552
Effect of Hydralazine on Alzheimer's Disease (EHSAN)
The Effect of Hydralazine on the Early Stage of Alzheimer's Disease: A Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study aim:
- Determination and comparison of the effect of 75mg (25mg TDS) hydralazine vs. placebo in patients with mild to moderate Alzheimer's disease.
- Development of an electronic Case Report Form (CRF) and push notification system to remind patients (and/or caregivers) of drug intake to improve drug intake adherence and reduce follow-up losses.
- Evaluation of the prognostic accuracy of olfactory tests to predict the changes in cognition and performance of patients with mild to moderate Alzheimer's disease.
Design:
This is a phase III, triple-blind, parallel double-armed randomized clinical trial with an allocation ratio of 1-1 to the intervention and placebo arms. This trial will be conducted on 424 randomly selected patients using random permuted blocks.
Settings and conduct:
All patients who are identified as potentially eligible by the supporting neurologists and psychiatrists will be referred to Adineh Clinic to evaluate their cognitive function, assess for inclusion and exclusion criteria and obtain informed consent. The two arms of the study are hydralazine 75mg (25mg three times per day) or hydralazine placebo. A follow-up evaluation will continue for one year after drug administration. The participants, outcome assessors, researchers, and data analyzers will be blinded to the study arms.
Participants/Inclusion and exclusion criteria:
patients over the age of 49 and over who are diagnosed with mild to moderate AD will be included in this study; dementia patients with etiologies other than AD (i.e. vascular dementia) will not be included.
Intervention groups:
The two arms of the study are Hydralazine 75mg (25mg three times per day) or Hydralazine placebo.
Main outcome variables:
Various cognitive and function tests for patients and caregivers, olfactory tests, biochemistry as well as drug side effects will be assessed regularly over the period of follow-up.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Masoud Mirzaei, MD, PhD
- Phone Number: +98-913-4509917
- Email: mmirzaei@ssu.ac.ir
Study Contact Backup
- Name: Nastaran- Ahmadi, PhD
- Phone Number: +98-913-3514827
- Email: ahmadi.psy@gmail.com
Study Locations
-
-
-
Yazd, Iran, Islamic Republic of, 8916713151
- Recruiting
- Adineh Health Centre
-
Contact:
- Behnam Bagheri, MSc.
- Phone Number: +98-35-38275414
- Email: behnambagheri222@gmail.com
-
Contact:
- Nastaran Ahmadi, PhD
- Phone Number: +98-35-38275414
- Email: ahmadi.psy@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnoses of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
- Presence of a caregiver (friend or relative) who can assume responsibility for medication administrations, accompany the patient to all visits, and rate patient's condition.
- Written informed consent form from both the patient (or surrogate) and caregiver.
- A Mini-Mental State Examination score between 12 and 26 inclusive.
- Prescription of donepezil (5-10mg/d), rivastigmine (3-6mg/d), galantamine or galantamine ER (8-16mg/d) for a minimum of 4 weeks prior to randomization.
- Agreement not to take hydralazine.
- Age 49 and over.
Exclusion Criteria:
- Non-Alzheimer primary dementia diagnosis (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia, vitamin B-12 deficiency, hypothyroidism).
- Diagnosis of any of the following conditions; major depression, delirium, alcohol or psychoactive substance abuse or dependency, schizophrenia, or delusional disorder as defined by Diagnostic and Statistical Manual (DSM)-IV.
- Diagnosis of systemic illnesses that would interfere with participation in the study or decrease the life expectancy to less than one year.
- Currently being treated with hydralazine or a history of intolerance to oral therapy with hydralazine
- Any intravenous treatment for heart failure, except IV furosemide (e.g. IV inotropes, pressors, nitrates or nesiritide) at the time of screening.
- Systolic blood pressure <100 mmHg, reversible etiology of acute heart failure such as myocarditis, acute myocardial infarction-over the past 4 weeks, arrhythmia and existence of pacing device (Acute myocardial infarction is defined as symptoms and major electrocardiogram (ECG) changes (i.e., ST segment elevations), and arrhythmia includes unstable heart rates above 120/min or below 50/min).
- Existence of severe congenital heart disease (such as uncorrected tetralogy of fallot or transposition of the aorta) and severe aortic or mitral stenosis or severe rheumatic mitral regurgitation.
- Concurrent use of phosphodiesterase type 5 (PDE5) inhibitors (e.g. Viagra, Etc.)
- Cardiac revascularization within the last 3 months or likelihood of requiring coronary revascularization within the study period. eGFR (Glomerular Filtration Rate) < 15ml/min/1.73m2, or on regular dialysis, or planned dialysis within the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Hydralazine hydrochloride 25mg
Hydralazine hydrochloride (25mg tablets) every eight hours (TDS)
|
Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
|
Placebo Comparator: Placebo
Placebo tablets (identical in shape to the active comparator) every eight hours (TDS)
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The progression of of Alzheimer's disease
Time Frame: Three months after recruitment.
|
The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory
|
Three months after recruitment.
|
The progression of of Alzheimer's disease
Time Frame: Six months after recruitment.
|
The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory
|
Six months after recruitment.
|
The progression of of Alzheimer's disease
Time Frame: Nine months after recruitment.
|
The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory
|
Nine months after recruitment.
|
The progression of of Alzheimer's disease
Time Frame: Twelve months after recruitment.
|
The progression of of Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using the Alzheimer's Disease Assessment Scale-Cognitive Sub-scale inventory
|
Twelve months after recruitment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Function of patients with Alzheimer's disease
Time Frame: Three months after recruitment
|
Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale
|
Three months after recruitment
|
Function of patients with Alzheimer's disease
Time Frame: Six months after recruitment
|
Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale
|
Six months after recruitment
|
Function of patients with Alzheimer's disease
Time Frame: Nine months after recruitment
|
Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale
|
Nine months after recruitment
|
Function of patients with Alzheimer's disease
Time Frame: Twelve months after recruitment
|
Changes in the function of patients with Alzheimer's disease in the hydralazine-treated group compared to placebo- treated using Lawton Activity of Daily Living Scale
|
Twelve months after recruitment
|
Cognition of patients with Alzheimer's disease
Time Frame: Three months after recruitment
|
Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination
|
Three months after recruitment
|
Cognition of patients with Alzheimer's disease
Time Frame: Six months after recruitment
|
Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination
|
Six months after recruitment
|
Cognition of patients with Alzheimer's disease
Time Frame: Nine months after recruitment
|
Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination
|
Nine months after recruitment
|
Cognition of patients with Alzheimer's disease
Time Frame: Twelve months after recruitment
|
Changes in the cognition of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Mini Mental State Examination
|
Twelve months after recruitment
|
Behavior of patients with Alzheimer's disease
Time Frame: Three months after recruitment
|
Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory
|
Three months after recruitment
|
Behavior of patients with Alzheimer's disease
Time Frame: Six months after recruitment
|
Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory
|
Six months after recruitment
|
Behavior of patients with Alzheimer's disease
Time Frame: Nine months after recruitment
|
Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory
|
Nine months after recruitment
|
Behavior of patients with Alzheimer's disease
Time Frame: Twelve months after recruitment
|
Changes in the behaviour of the patients with Alzheimer's disease in the hydralazine-treated group compared to placebo-treated using Nero-Psychiatry Inventory
|
Twelve months after recruitment
|
Caregiver's spent time
Time Frame: Three months after recruitment
|
Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale
|
Three months after recruitment
|
Caregiver's spent time
Time Frame: Six months after recruitment
|
Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale
|
Six months after recruitment
|
Caregiver's spent time
Time Frame: Nine months after recruitment
|
Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale
|
Nine months after recruitment
|
Caregiver's spent time
Time Frame: Twelve months after recruitment
|
Changes in caregiver's spent time for the patients in the hydralazine-treated group compare to placebo using Caregiver Activity Scale
|
Twelve months after recruitment
|
Olfactory sense
Time Frame: Three months after recruitment
|
the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'
|
Three months after recruitment
|
Olfactory sense
Time Frame: Six months after recruitment
|
the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'
|
Six months after recruitment
|
Olfactory sense
Time Frame: Nine months after recruitment
|
the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'
|
Nine months after recruitment
|
Olfactory sense
Time Frame: Twelve months after recruitment
|
the changes in the olfactory sense in the hydralazine-treated group compare to placebo using 'peanut butter smelling test'
|
Twelve months after recruitment
|
Drug side effects
Time Frame: Daily records in the provided notebook and reported three month after recruitment. Urgent matter can be reported any time to the provided hotline.
|
The side effects of hydralazine-treated group compare to placebo-treated
|
Daily records in the provided notebook and reported three month after recruitment. Urgent matter can be reported any time to the provided hotline.
|
Drug side effects
Time Frame: Daily records in the provided notebook and reported six month after recruitment. Urgent matter can be reported any time to the provided hotline.
|
The side effects of hydralazine-treated group compare to placebo-treated
|
Daily records in the provided notebook and reported six month after recruitment. Urgent matter can be reported any time to the provided hotline.
|
Drug side effects
Time Frame: Daily records in the provided notebook and reported nine month after recruitment. Urgent matter can be reported any time to the provided hotline.
|
The side effects of hydralazine-treated group compare to placebo-treated
|
Daily records in the provided notebook and reported nine month after recruitment. Urgent matter can be reported any time to the provided hotline.
|
Drug side effects
Time Frame: Daily records in the provided notebook and reported twelve month after recruitment. Urgent matter can be reported any time to the provided hotline.
|
The side effects of hydralazine-treated group compare to placebo-treated
|
Daily records in the provided notebook and reported twelve month after recruitment. Urgent matter can be reported any time to the provided hotline.
|
Collaborators and Investigators
Investigators
- Study Chair: Hamid Mirzaei, PhD, Shahid Sadoughi University of Medical Sciences
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRCT20200711048075N1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Study Data/Documents
-
Informed Consent Form
Information comments: All requests should be submitted to the contact us/about at the study website or study.ehsan@gmail.com
-
Clinical Study Report
Information comments: All requests should be submitted to the contact us/about at the study website or study.ehsan@gmail.com
-
Study Protocol
Information comments: All requests should be submitted to the contact us/about at the study website or study.ehsan@gmail.com
-
Statistical Analysis Plan
Information comments: All requests should be submitted to the contact us/about at the study website or study.ehsan@gmail.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States